Cellectis S.A.(CLLS), a biotechnology company focused on gene-editing technologies, presented promising data at the American Association for Cancer Research - Immuno-oncology or AACR-IO 2025.
The company showcased a novel strategy aimed at enhancing CAR T cell efficacy in treating solid tumors.
The approach utilizes Cellectis' TALEN gene editing technology to develop "Smart CAR T cells" that express a recombinant IL-2 variant or IL-2v immunocytokine to localize anti-tumor activity within the tumor microenvironment, reducing systemic toxicity.
The data presented demonstrated that the CAR T cells, engineered to induce IL-2v expression in response to tumor-specific cues, led to significant boosts in anti-tumor activity both in vitro and in vivo. Cellectis' strategy offers a safer and more effective method for enhancing CAR T cell therapy for solid tumors.
CLLS closed Tuesday's (Feb.25 2025) trading at $1.49 down by 1.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.